Tabula Rasa HealthCare, Inc.

Tabula Rasa HealthCare, Inc. is a U. S. -based company specializing in integrated clinical pharmacy and technology solutions to optimize medication management for individuals with complex health needs and the healthcare organizations that serve them.

Founded in 2009 in Moorestown, US, Tabula Rasa HealthCare, Inc. focuses on enhancing medication management through innovative solutions. The company has not undergone notable pivots or changes in strategy and does not have reported parent or subsidiary companies. The founders include Calvin Knowlton, Melissa Fernald, and Orsula Knowlton.

The current CEO is Brian Adams. As of September 28, 2016, the company completed an ADD-ON round, raising USD 570. 00 mn in a Trade Sale, with a total amount raised of USD 24. 80 mn from various funding rounds.

Tabula Rasa HealthCare, Inc. delivers integrated clinical pharmacy and technology solutions that enhance medication management for patients with complex care requirements and the healthcare providers serving them. Their core offerings include MedWise®, a proprietary technology for comprehensive multi-drug analysis that identifies health risks and mitigates adverse drug events. The company serves over 100,000 patients nationwide, focusing on medication therapy management, transitions of care, and in-home pharmacy support through a network of over 64,000 pharmacies across all 50 states and Washington, D.

C. In 2022, Tabula Rasa HealthCare, Inc. reported revenues of USD 299. 52 mn, with an EBITDA of USD -35.

99 mn. The company generates revenue primarily through its pharmacy management services and technology solutions, employing a business-to-business (B2B) model that establishes long-term partnerships with various healthcare organizations, including both commercial plans and government programs. Revenue is derived from service agreements and subscriptions to their medication management services, which form a significant part of their revenue structure. Looking ahead, Tabula Rasa HealthCare, Inc.

is focused on expanding its business following its IPO in September 2016, which raised USD 59. 40 mn. The company intends to use these funds to support the development of new products and services aimed at improving medication management. Additionally, future initiatives may include entering new geographic markets to broaden their client base, although specific regions have not been disclosed.

The company will leverage recent funding to enhance service offerings and operational capabilities.